TRIUMEQ Has Few Significant DDIs 1
| Commonly used medications | Interactions |
| Oral contraceptives | No |
| H2-antagonists (including ranitidine, cimetidine) | No |
| Hepatitis C protease inhibitors (telaprevir, boceprevir) | No |
| Prednisone | No |
| Rifabutin | No |
| Methadone | Dosing adjustment likely not needed for most patients |
| Metformin | Close monitoring is recommended when starting or stopping TRIUMEQ and metformin together as a dose adjustment may be needed for metformin |
| Multivitamins, calcium supplements, iron supplements | TRIUMEQ is recommended to be administered 2 hours before or 6 hours after taking these agents |
| Magnesium/aluminium-containing antacids | TRIUMEQ is recommended to be administered 2 hours before or 6 hours after taking these agents |
| Rifampicin, efavirenz, nevirapine, and tipranavir/r | Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with these agents, the use of TRIUMEQ is not recommended for patients taking these medicines |
- Co-administration with dofetilide is contraindicated 1
- Co-administration with oxcarbazepine, phenytoin, phenobarbital, carbamazepine, or St John’s Wort should be avoided because there are insufficient data to make dosing recommendations 1
- Co-administration with etravirine is not recommended unless patient is also receiving atazanavir/r, lopinavir/r or darunavir/r 1
Dolutegravir is eliminated primarily by UGT1A1. Abacavir and lamivudine are not significantly metabolised by CYP enzymes. 1
For further information, please see the Summary of Product Characteristics.
DDIs=drug-drug interactions.
References:
TRIUMEQ, TIVICAY, ZIAGEN, EPIVIR, KIVEXA, EPZICOM, TRIZIVIR, COMBIVIR
son marcas registradas del grupo de compañías ViiV Healthcare